Clinical application analysis of andrographolide total ester sulfonate injection, a traditional Chinese medicine licensed in China

  • Ying Zhao (赵 瑛)
  • Pu Huang (黄 璞)
  • Zhe Chen (陈 喆)
  • Si-wei Zheng (郑思维)
  • Jin-yang Yu (喻锦扬)
  • Chen Shi (史 琛)Email author


Andrographolide total ester sulfonate (ATES) injection is one of the products of traditional Chinese medicine (TCM) currently used against viral infection in China. ATES injection was approved for manufacturing and marketing in January 2002. It is indicated for acute respiratory infections, tonsillitis, chronic obstructive pulmonary disease, influenza, foot and mouth disease, bronchiolitis, herpangina, mumps, infectious mononucleosis and psychosis. However, its usage also carries risk. We investigated the use of ATES at the Wuhan Union Hospital from January 2014 to December 2014 and evaluated its real-world clinical application using the hospital centralized monitoring method. A total of 848 cases were enrolled in this study. In these cases, it was mainly used for postoperative anti-inflammation and treating upper respiratory infection, pneumonia and bronchitis. Among them, 39.86% were contraindicated. Irregular medication of adults and children accounted for 1.91% and 23.38%, respectively. Improper choice of solvent accounted for 3.18%. The choice of intravenous drip versus aerosol inhalation was reasonable. A case of adverse events (AEs) was observed in the monitoring period, and the incidence of adverse drug reaction (ADR) of ATES injection was 0.12%. ATES injection in our hospital is relatively safe with a low incidence of adverse reactions. The study assesses the clinical usage and adverse reactions of ATES injection, and provides suggestions for rational use in clinical practice.

Key words

andrographolide total ester sulfonate hospital centralized monitoring post-marketing reassessment clinical use adverse reaction 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Seniya C, Shrivastava S, Singh SK, et al. Analyzing the interaction of a herbal compound Andrographolide from Andrographis paniculata as a folklore against swine flu (H1N1). Asian Pac J Trop Med, 2014,4(Suppl 2):S624–S30CrossRefGoogle Scholar
  2. 2.
    Preet R, Chakraborty B, Siddharth S, et al. Synthesis and biological evaluation of andrographolide analogues as anti-cancer agents. Eur J Med Chem, 2014,85(15):95–106CrossRefPubMedGoogle Scholar
  3. 3.
    Wen L, Xia N, Chen X, et al. Activity of antibacterial, antiviral, anti-inflammatory in compounds andrographolide salt. Eur J Pharmacol, 2014, 740: 421–427CrossRefPubMedGoogle Scholar
  4. 4.
    Abu-Ghefreh AA, Canatan H, Ezeamuzie CI. In vitro and in vivo anti-inflammatory effects of andrographolide. Int Immunopharmacol, 2009,9(3):313–318CrossRefPubMedGoogle Scholar
  5. 5.
    Lee TY, Chang HH, Wen CK, et al. Modulation of thioacetamide-induced hepatic inflammations, angiogenesis and fibrosis by andrographolide in mice. J Ethnopharmacol, 2014,158 Pt A:423–430CrossRefPubMedGoogle Scholar
  6. 6.
    Okhuarobo A, Ehizogie Falodun J, Erharuyi O, et al. Harnessing the medicinal properties of Andrographis paniculata for diseases and beyond: a review of its phytochemistry and pharmacology. Asian Pac J Trop Med, 2014,4(3):213–22CrossRefGoogle Scholar
  7. 7.
    Yu Z, Lu B, Sheng Y, et al. Andrographolide ameliorates diabetic retinopathy by inhibiting retinal angiogenesis and inflammation. BBA, 2015,1850(4):824–831PubMedGoogle Scholar
  8. 8.
    Shinde N, Chauhan AS, Gupta SK, et al. Antifertility studies of curcumin and andrographolide combination in female rats. Asian Pac J Reprod, 2015,4(3):188–194CrossRefGoogle Scholar
  9. 9.
    Oppenheimer J. Device selection and outcomes of aerosol therapy: Evidence-Based Guidelines. Ann Allerg Asthma Im, 2006,96(6):8815CrossRefGoogle Scholar
  10. 10.
    Anderson PJ. Delivery options and devices for aerosolized therapeutics. Chest. 2001,120(3 Suppl):89S–93SCrossRefPubMedGoogle Scholar
  11. 11.
    Kuhn RJ. Formulation of aerosolized therapeutics. Chest, 2001,120(3 Suppl):94S–98SCrossRefPubMedGoogle Scholar
  12. 12.
    Burchett DK, Darko W, Zahra J, et al. Mixing and compatibility guide for commonly used aerosolized medications. Am J Health Syst Pharm, 2010,67(3):227–230CrossRefPubMedGoogle Scholar
  13. 13.
    Geng L, Fang B, Chen S, et al. Meta-analysis of different administrative route of Xiyanping injection for treating respiratory tract infection in children. Mod J Integr Chin Tradit West Med, 2014,23(29):3214–3216Google Scholar
  14. 14.
    Wang YP, Jiao K, He ZF. Systematic evaluation of adverse drug reactions of Xiyanping injection from documents. Chin J Exp Med Formul, 2011,17(24):236–239Google Scholar

Copyright information

© Huazhong University of Science and Technology and Springer-Verlag Berlin Heidelberg 2017

Authors and Affiliations

  • Ying Zhao (赵 瑛)
    • 1
  • Pu Huang (黄 璞)
    • 1
  • Zhe Chen (陈 喆)
    • 1
  • Si-wei Zheng (郑思维)
    • 1
  • Jin-yang Yu (喻锦扬)
    • 2
  • Chen Shi (史 琛)
    • 1
    Email author
  1. 1.Department of Pharmacy, Union Hospital, Tongji Medical CollegeHuazhong University of Science and TechnologyWuhanChina
  2. 2.Center for ADR Monitoring of GuangdongGuangzhouChina

Personalised recommendations